Algert Global LLC Grows Holdings in Amedisys Inc (AMED)
Algert Global LLC boosted its position in shares of Amedisys Inc (NASDAQ:AMED) by 9.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,539 shares of the health services provider’s stock after buying an additional 1,403 shares during the period. Algert Global LLC’s holdings in Amedisys were worth $1,942,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC purchased a new position in Amedisys during the 3rd quarter worth $203,000. Ibex Investors LLC purchased a new position in shares of Amedisys in the 3rd quarter valued at $215,000. Itau Unibanco Holding S.A. purchased a new position in shares of Amedisys in the 2nd quarter valued at $149,000. Hsbc Holdings PLC purchased a new position in shares of Amedisys in the 3rd quarter valued at $224,000. Finally, Laurion Capital Management LP purchased a new position in shares of Amedisys in the 3rd quarter valued at $242,000. Institutional investors own 92.39% of the company’s stock.
Amedisys stock opened at $135.48 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $4.30 billion, a PE ratio of 60.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.29. Amedisys Inc has a 1-year low of $49.80 and a 1-year high of $140.91.
A number of research analysts have recently issued reports on AMED shares. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. Craig Hallum downgraded Amedisys from a “buy” rating to a “hold” rating and cut their price target for the company from $116.00 to $104.00 in a report on Friday, October 26th. Canaccord Genuity started coverage on Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target on the stock. SunTrust Banks lifted their price target on Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday, October 11th. Finally, UBS Group started coverage on Amedisys in a report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Amedisys has an average rating of “Buy” and an average price target of $107.08.
In other news, COO Christopher Gerard sold 7,892 shares of the firm’s stock in a transaction on Friday, November 9th. The stock was sold at an average price of $119.02, for a total value of $939,305.84. Following the completion of the sale, the chief operating officer now owns 29,429 shares of the company’s stock, valued at approximately $3,502,639.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott G. Ginn sold 7,640 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $117.41, for a total value of $897,012.40. The disclosure for this sale can be found here. Insiders sold a total of 37,486 shares of company stock valued at $4,449,649 in the last three months. Insiders own 2.60% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Story: Discount Rate
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.